Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2150 with Chemo and PD-1 or CD47 Antibody in Solid Tumors
NCT04588324Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2020
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
A Phase 2 trial of SHR2150 in solid tumor, sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
SHR2150
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04588324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588324.